tumor necrosis factor receptor

Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.

Teneliximab (BMS 224819) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interactions.Teneliximab exerts its partial agonist activity through CD40 and peripheral B-cell depletion, and may be used to study organ transplant rejection and rheumatoid arthritis.

Etanercept is a fusion protein consisting of the soluble portion of the p75-tumor necrosis factor receptor (TNFR) and the Fc fragment of human IgG1 and is commonly used to treat patients with rheumatoid arthritis.[1]

Revdofilimab (ABBV-368) is a human IgG monoclonal antibody targeting Tumor Necrosis Factor Receptor superfamily member 4 (OX 40) with potential anticancer activity for the study of metastatic solid tumors and non-small cell lung cancer.

Onercept, a recombinant soluble form of the human tumor necrosis factor-alpha (TNF-α) p55 receptor, is utilized in the study of Crohn's disease [1].

PTX-35 is a potential first-in-class agonistic monoclonal antibody targeting Tumor Necrosis Factor Receptor Superfamily Member 25 (TNFRSF25, also known as DR3). By specifically activating the TNFRSF25 signaling pathway, the compound modulates T-cell immune responses, particularly within the tumor microenvironment. In experimental studies, PTX-35 has been demonstrated to reduce the suppressive activity of regulatory T cells (Tregs) and enhance CD4+ effector T-cell responses to tumor antigens, exhibiting significant anti-tumor potential.

Anti-TNFRSF5/CD40 Antibody is a highly specialized monoclonal antibody target the human tumor necrosis factor receptor superfamily member 5, which is also widely known as CD40, modulation of co-stimulatory signaling pathways and immune cell activation across various preclinical experimental models to regulate humoral immunity and dendritic cell maturation.

Anti-TNFRSF21/DR6/CD358 Antibody is a humanized monoclonal antibody targeting Death Receptor 6 (DR6, also known as TNFRSF21). DR6 is a member of the tumor necrosis factor receptor (TNFR) superfamily containing an intracellular death domain. It plays a pivotal role in nervous system development by binding to amyloid precursor protein (APP) to trigger axon pruning and neuronal death. Additionally, DR6 is overexpressed in various tumor cells and is involved in regulating angiogenesis and cell survival. Featuring a huIgG1 heavy chain and a hu-kappa light chain, this antibody is utilized to study DR6-mediated apoptotic signaling, mechanisms of neurodegenerative diseases, and the modulation of the tumor immune microenvironment.

Afimkibart (PF06480605) is a humanised monoclonal antibody targeting TL1A (TNF-like Ligand 1A), which blocks TL1A-DR3 (death domain receptor 3) signalling on restrictive immune cells and fibroblasts. It can be used for inflammatory bowel disease and ulcerative colitis.

Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is a rat-derived IgG2a monoclonal antibody targeting mouse CD40, a type I transmembrane glycoprotein within the tumor necrosis factor receptor (TNFR) superfamily. CD40 functions as a costimulatory molecule, activating B cells, dendritic cells, monocytes, and other antigen-presenting cells (APC), thereby enhancing antitumor T cell responses.

TRX-518 is a humanized agonist antibody targeting the glucocorticoid-induced tumor necrosis factor receptor (GITR). It specifically targets GITR⁺ regulatory T cells (Tregs) and CD45RA⁻Foxp3⁺ effector Tregs (eTregs) within regulatory T cells, effectively reducing the number of Tregs in circulation and within tumors.

Nesfrotamig is an immunoglobulin (H-γ1-scFv-L-κ) dimer humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (ERBB2) and human tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Nesfrotamig shows potential for use in ERBB2-positive tumor diseases, such as breast cancer and gastric cancer.

Opamtistomig is a humanized monoclonal antibody immunoglobulin (H-γ1-scFv-L-κ) dimer targeting human programmed death-ligand 1 (PD-L1), CD274, and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). It is anticipated for use in research on various solid tumors and hematologic malignancies.

BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody that targets the glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR). It binds to GITR and enhances the activation of T effector cells while deactivating T regulatory cells. BMS-986156 is applicable for research in advanced solid tumors.

HFB-200301 is an IgG1 antibody that targets the tumor necrosis factor receptor 2 (TNFR2). In the presence of sTNF, HFB-200301 enhances the activation of TNFR2, which then stimulates related signaling pathways, such as the activation of NF-κB dimers through the classical NF-κB pathway, influencing cell metabolism and gene expression. HFB-200301 shows potential for cancer research.

Cenzestotug is a monoclonal antibody targeting the human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). By binding to TNFRSF4, Cenzestotug activates associated immune cells, exerting immunostimulatory and anti-tumor effects. It shows potential for research in cancer immunotherapy.

Ramantamig is a humanized monoclonal antibody that targets human CD3ε, GPRC5D, and TNFRSF17 [tumor necrosis factor receptor superfamily member 17]. It holds potential for cancer research, particularly focusing on hematologic malignancies such as multiple myeloma.